Riomet | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Riomet
US Patents

PharmaCompass Sponsored Ads

Contact Supplier

Metformin

Contact Supplier

Chirogate is a professional Prostaglandin manufacturer.

Contact Supplier

PharmaCompass Sponsored Ads

Contact Supplier

Skyepharma, an Expert and Innovative CDMO Partner for tailor-made solutions in complex oral solids and bioproduction.

Contact Supplier

jdmfs-not-supported-m-2025-06-30

Riomet

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

178 API Suppliers, 57 USDMF, 43 CEP/COS, 13 JDMF, 31 EU WC, 99 KDMF, 39 NDC API, 45 Listed Suppliers, $ API Reference Price

178 API Suppliers
57 USDMF
43 CEP/COS
13 JDMF
31 EU WC
99 KDMF
39 NDC API
45 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

33 Drugs in Development

33 Drugs in Development

FINISHED DOSAGE FORMULATIONS

1942 FDF Dossiers, 431 FDA Orange Book, 534 Europe, 134 Canada, 136 Australia, 140 South Africa, 567 Listed Dossiers

1942 FDF Dossiers
431 FDA Orange Book
534 Europe
134 Canada
136 Australia
140 South Africa
567 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 500MG;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 2.5MG;1GM, TABLET;ORAL - 2.5MG;500MG, TABLET;ORAL - 2.5MG;850MG, TABLET;ORAL - EQ 12.5MG BASE;1GM, TABLET;ORAL - EQ 12.5MG BASE;500MG, TABLET;ORAL - 1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 625MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 850MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 150MG;1GM, TABLET, EXTENDED RELEASE;ORAL - 150MG;500MG, TABLET, EXTENDED RELEASE;ORAL - 50MG;1GM, TABLET, EXTENDED RELEASE;ORAL - 50MG;500MG, TABLET;ORAL - 1.25MG;250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 2.5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FOR SUSPENSION, EXTENDED RELEASE;ORAL - 500MG/5ML, TABLET, EXTENDED RELEASE;ORAL - 1GM, TABLET, EXTENDED RELEASE;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;ORAL - 500MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 1GM, TABLET, EXTENDED RELEASE;ORAL - 500MG, TABLET;ORAL - 500MG;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 850MG;EQ 15MG BASE, TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 15MG BASE, TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 30MG BASE, TABLET;ORAL - 1GM;EQ 50MG BASE, TABLET;ORAL - 500MG;EQ 50MG BASE, TABLET;ORAL - 500MG;1MG, TABLET;ORAL - 500MG;2MG

TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 500MG;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 2.5MG;1GM
TABLET;ORAL - 2.5MG;500MG
TABLET;ORAL - 2.5MG;850MG
TABLET;ORAL - EQ 12.5MG BASE;1GM
TABLET;ORAL - EQ 12.5MG BASE;500MG
TABLET;ORAL - 1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 625MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 850MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 150MG;1GM
TABLET, EXTENDED RELEASE;ORAL - 150MG;500MG
TABLET, EXTENDED RELEASE;ORAL - 50MG;1GM
TABLET, EXTENDED RELEASE;ORAL - 50MG;500MG
TABLET;ORAL - 1.25MG;250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 2.5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
FOR SUSPENSION, EXTENDED RELEASE;ORAL - 500MG/5ML
TABLET, EXTENDED RELEASE;ORAL - 1GM
TABLET, EXTENDED RELEASE;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
SOLUTION;ORAL - 500MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 1GM
TABLET, EXTENDED RELEASE;ORAL - 500MG
TABLET;ORAL - 500MG;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 850MG;EQ 15MG BASE
TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 15MG BASE
TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 30MG BASE
TABLET;ORAL - 1GM;EQ 50MG BASE
TABLET;ORAL - 500MG;EQ 50MG BASE
TABLET;ORAL - 500MG;1MG
TABLET;ORAL - 500MG;2MG

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 2 Minakem, 8 Evonik, 7 Rochem International Inc, 23 SPI Pharma, 19 DKSH, 2 Pharm-RX Chemical, 13 Boai NKY Pharmaceuticals Ltd, 9 Gangwal Healthcare, 12 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 2 Pfanstiehl, 1 ACG Worldwide, 12 Actylis, 3 Aeon Procare, 2 Alcedo Pharmachem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 4 Ashland, 1 Avesta Pharma, 38 BASF, 1 Bioplus Life Sciences, 2 CD Formulation, 2 Clariant, 27 Corel Pharma Chem, 7 DFE Pharma, 1 Doshion Polyscience, 1 Esteem Industries, 2 Finar, 13 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 5 Ideal Cures, 5 Ingredion Pharma Solutions, 26 Kerry, 5 Keval Exports, 5 Kima Chemical, 6 Lonza Capsugel, 5 Lubrizol Life Science Health, 22 Microlex e.U, 2 Nanjing Bold Chemical, 3 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 5 Novo Excipients, 5 Pharmatrans-Sanaq, 11 Pluviaendo, 5 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 35 Roquette, 14 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 4 Silverline Chemicals, 4 The Dow Chemical Company, 3 Ulanqab Kema New Material, 3 Valens Pharmachem, 4 Vasa Pharmachem, 2 Vertellus, 2 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

108 Fillers, Diluents & Binders, 63 Coating Systems & Additives, 57 Direct Compression, 53 Thickeners and Stabilizers, 52 Disintegrants & Superdisintegrants, 52 Controlled & Modified Release, 48 Solubilizers, 46 Granulation, 42 Taste Masking, 40 Film Formers & Plasticizers, 39 Topical, 30 Parenteral, 30 Lubricants & Glidants, 25 Chewable & Orodispersible Aids, 16 Co-Processed Excipients, 15 Rheology Modifiers, 14 Emulsifying Agents, 10 API Stability Enhancers, 6 Surfactant & Foaming Agents, 5 Empty Capsules, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

108 Fillers, Diluents & Binders
63 Coating Systems & Additives
57 Direct Compression
53 Thickeners and Stabilizers
52 Disintegrants & Superdisintegrants
52 Controlled & Modified Release
48 Solubilizers
46 Granulation
42 Taste Masking
40 Film Formers & Plasticizers
39 Topical
30 Parenteral
30 Lubricants & Glidants
25 Chewable & Orodispersible Aids
16 Co-Processed Excipients
15 Rheology Modifiers
14 Emulsifying Agents
10 API Stability Enhancers
6 Surfactant & Foaming Agents
5 Empty Capsules
5 Coloring Agents
4 Vegetarian Capsules
1 Soft Gelatin

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 374 News #PharmaBuzz

1 Data Compilation #PharmaFlow
374 News #PharmaBuzz

GLOBAL SALES INFORMATION

96 US Medicaid Prescriptions, 494 Regulatory FDF Prices, 25 Annual Reports

96 US Medicaid Prescriptions
494 Regulatory FDF Prices
25 Annual Reports

MARKET PLACE

91 APIs, 51 FDF Dossiers

91 APIs
51 FDF Dossiers

PATENTS & EXCLUSIVITIES

610 US Patents, 54 US Exclusivities, 17 Health Canada Patents

610 US Patents
54 US Exclusivities
17 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 1 USP, 7 Others

3 EDQM
1 USP
7 Others

ANALYTICAL

2 BioAnalytical Methods, 1 Analytical Methods

2 BioAnalytical Methods
1 Analytical Methods

$ API Ref.Price (USD/KG) : 4 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

610 All

01 100ASTRAZENECA AB

02 350BOEHRINGER INGELHEIM

03 116JANSSEN PHARMS

04 26MSD SUB MERCK

05 1SANTARUS INC

06 1SUN PHARM

07 16TAKEDA PHARMS USA

filter Patent Number Reset all filters

610 All

01 510022379*PED

02 1210258637*PED

03 410596120*PED

04 410610489*PED

05 96515117

06 57326708

07 97407955

08 127579449

09 127713938

10 17780987

11 27785627

12 27807689

13 97919598

14 247943582

15 87943788

16 27959946

17 48080580

18 28173663

19 248222219

20 28288539

21 28414921

22 98501698

23 248513202

24 48551957

25 78628799

26 58673927

27 58685934

28 48716251

29 38846695

30 98883805

31 28900638

32 29101660

33 99155705

34 29173859

35 49308204

36 29320714

37 39339472

38 99415016

39 49439902

40 49555001

41 99616028

42 169949997

43 89949998

44 19962336

45 910022379

46 1210258637

47 410406172

48 1610596120

49 410610489

50 310973827

51 310973827*PED

52 1211090323

53 1211090323*PED

54 311564886

55 411576894

56 811666590

57 411813275

58 2411833166

59 511911388

60 1212115179

61 812263153

62 96515117*PED

63 57326708*PED

64 97407955*PED

65 127579449*PED

66 127713938*PED

67 97919598*PED

68 87943582*PED

69 87943788*PED

70 88222219*PED

71 28414921*PED

72 98501698*PED

73 88513202*PED

74 48551957*PED

75 58673927*PED

76 58685934*PED

77 48716251*PED

78 38846695*PED

79 98883805*PED

80 59155705*PED

81 29173859*PED

82 59415016*PED

83 29555001*PED

84 99616028*PED

85 89949997*PED

86 89949998*PED

filter API Patent Reset all filters

610 All

01 121Y

02 489Blank

filter FDF Patent Reset all filters

610 All

01 222Y

02 388Blank

filter Expiration Date Reset all filters

610 All

01 22025-03-15

02 12025-03-23

03 242025-04-11

04 92025-05-02

05 22025-06-24

06 102025-07-13

07 92025-10-04

08 82025-10-11

09 92025-11-02

10 92025-11-26

11 92026-04-04

12 92026-05-26

13 42026-07-31

14 52026-11-24

15 22027-01-22

16 122027-04-15

17 72027-05-04

18 52027-05-24

19 92027-06-20

20 82027-07-14

21 122027-10-15

22 72027-11-04

23 242027-12-03

24 92027-12-20

25 82028-01-14

26 42028-03-21

27 82028-06-03

28 22028-06-27

29 22028-07-21

30 122028-08-01

31 42028-09-21

32 22029-01-21

33 122029-02-01

34 22029-02-03

35 242029-02-26

36 212029-04-02

37 22029-05-24

38 82029-08-26

39 132029-10-02

40 42029-10-14

41 92029-12-16

42 122030-02-11

43 52030-04-10

44 42030-04-14

45 92030-05-21

46 52030-05-26

47 32030-06-04

48 42030-06-15

49 92030-06-16

50 42030-07-06

51 42030-07-13

52 42030-09-30

53 82030-10-21

54 92030-11-12

55 52030-11-21

56 52030-11-26

57 32030-12-04

58 42031-03-30

59 92031-05-12

60 192032-03-07

61 42032-09-07

62 42033-03-06

63 22033-09-06

64 682034-04-03

65 162034-05-17

66 82034-06-11

67 242034-10-03

68 82034-11-17

69 82034-12-11

70 12035-05-01

Granules Metformin

Product Main Page

01

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

AGGSpend

Not Confirmed

ASTRAZENECA AB

AGGSpend

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-10-04

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 6515117

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 205649

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2025-10-04

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

AGGSpend

Not Confirmed

ASTRAZENECA AB

AGGSpend

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-10-04

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 6515117

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 205649

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2025-10-04

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

AGGSpend

Not Confirmed

ASTRAZENECA AB

AGGSpend

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-06-20

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 8501698

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 205649

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2027-06-20

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

AGGSpend

Not Confirmed

ASTRAZENECA AB

AGGSpend

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-10-04

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 6515117

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 205649

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2025-10-04

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

AGGSpend

Not Confirmed

ASTRAZENECA AB

AGGSpend

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-06-20

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 8501698

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 205649

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2027-06-20

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

AGGSpend

Not Confirmed

ASTRAZENECA AB

AGGSpend

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-05-26

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 8685934

Drug Substance Claim :

Drug Product Claim :

Application Number : 205649

Patent Use Code : U-1522

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2030-05-26

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

AGGSpend

Not Confirmed

ASTRAZENECA AB

AGGSpend

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-10-04

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

US Patent Number : 6515117

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 210874

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2025-10-04

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

AGGSpend

Not Confirmed

ASTRAZENECA AB

AGGSpend

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-10-04

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

US Patent Number : 6515117

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 210874

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2025-10-04

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

AGGSpend

Not Confirmed

ASTRAZENECA AB

AGGSpend

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-06-20

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

US Patent Number : 8501698

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 210874

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2027-06-20

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

10

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

AGGSpend

Not Confirmed

ASTRAZENECA AB

AGGSpend

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-06-20

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

US Patent Number : 8501698

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 210874

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2027-06-20

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

1
2
3
Last

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!